Data
- - - Truveta Data
      
      A complete, living view of patient care
    - Explore Truveta Data
  - - Capabilities
      
      Representative, complete, and real-time
  - - Evidence
      
      Build trust through rigorous analytics and expertise
    - - Trusted research environment
      - Evidence Services
Intelligence
- - - Truveta Intelligence
      
      Answers in minutes, not months
    - Explore Truveta Intelligence
  - - Capabilities
      
      Ask what matters now
    - - Ask
  - - Evidence
      
      Verify the methodology behind the results
    - - Verify
Customers
- - - Truveta customers
      
      Trusted by leading life science, public health, and healthcare organizations
  - - Who we serve
Research
About
- - - Saving Lives with Data
      
      Built with and owned by US health systems to improve patient care
Contact us
Sign in



Close

Research

Featured research

Hantavirus remains extremely rare in the US — but severe when it occurs • Since 2018, roughly 0.5 hantavirus cases per 1 million patients seeking care were identified. • Nearly half of patients with hantavirus were hospitalized within first 14 days.

Hantavirus remains extremely rare in the US — but severe when it occurs

Since 2018, roughly 0.3 hantavirus cases per 1 million patients seeking care each quarter were identified. Nearly half of patients with hantavirus were hospitalized within first 14 days. Of patients who were hospitalized, 85% were hospitalized prior to diagnosis or...

CDC study links later clinic visits to lower antihypertensive adherence

CDC study links later clinic visits to lower antihypertensive adherence

A CDC-led study published in the American Journal of Preventive Medicine used linked electronic health records and pharmacy dispensing data from Truveta to analyze 4,027,607 antihypertensive prescriptions among 936,502 US adults with hypertension. Compared with 7 am...

Estrogen-based hormone replacement therapy use is rising

Estrogen-based hormone replacement therapy use is rising

Estrogen-based hormone replacement therapy (HRT) prescribing more than doubled from 2018 to 2026. The largest increases were seen in patches and vaginal creams, with patch use more than tripling and vaginal cream use increasing more than fourfold. The rates of women...

Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval – Truveta research report cover image.

Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval

A large proportion of early users (36.1%) of oral semaglutide (Wegovy pill) had no prior evidence of GLP-1-based medication use, suggesting rapid uptake among patients new to taking GLP-1 medications. Among patients who previously used a GLP-1-based medication, most...

Featured research topics

GLP-1

Oncology

Flu/RSV

Measles

Cardiovascular